CVSA

Greetings, welcome to the Covista third quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note that this conference is being recorded. I will now turn the conference over to Jeremy Cohen, Vice President of Investor Relations. Thank you. You may go ahead.

Good afternoon, welcome to Covista's earnings call for the fiscal year 2026 third quarter results. On the call with me today are Steve Beard, Chairman and Chief Executive Officer of Covista, and Bob Phelan, Chief Financial Officer. Before I hand you over to Steve, I will take you through the legal safe harbor and cautionary declarations. Certain statements and projections of future results made in this presentation constitute forward-looking statements that are based on our current market, competitive, and regulatory expectations and subject to risks and uncertainties that could cause actual results to vary materially. We undertake no obligation to update publicly any forward-looking statement after this presentation, whether as a result of new information, future events, changes in assumptions, or otherwise. Please see our latest Form 10-K and Form 10-Q for a discussion of risk factors as they relate to forward-looking statements.

In today's presentation, we will use certain non-GAAP financial measures, and we refer you to the appendix in the presentation materials available on our investor relations website for reconciliations to the most directly comparable GAAP financial measures and related information. You will find a link to the webcast on our investor relations website at investors.covista.com. After this call, the presentation and webcast will be archived on the website for 30 days. I will now hand you over to Steve.

Thanks, Jeremy. Good afternoon, everyone, and thank you for joining us. This is our first earnings call as Covista. The name reflects what we've been building, a single platform for healthcare workforce development on a national scale, backed by the performance you're seeing in this quarter's results. The structural backdrop for our business hasn't changed and remains highly durable. There are roughly 700,000 healthcare jobs posted every month in the U.S. and only 306,000 unemployed healthcare workers to fill them. That's a patient care problem, not a staffing problem, and it's exactly what we were built to solve. 5 institutions, more than 24,000 healthcare graduates a year, deep clinical relationships, and a footprint that reaches communities most under strain.

We're increasingly connecting our market-leading capacity to produce healthcare workers directly to employers through programs that fund education, deliver clinical experience, and create hiring pathways. No one else does this at our scale. 3 things defined this quarter. First, we surpassed 100,000 students, achieved our 11th consecutive quarter of total enrollment growth, and delivered record enrollment at both Chamberlain and Walden. Second, Chamberlain returned to positive total enrollment growth ahead of our expectations. The operating changes that we committed to are in fact working. Third, the strength of our results gives us the confidence to raise both revenue and adjusted EPS guidance for the year. Total enrollment grew 6.8% in the quarter against near double-digit comparables a year ago. Walden has been compounding off an extraordinary base, and Chamberlain spent this fiscal year retooling its marketing and enrollment model.

As Chamberlain's recovery builds and Walden's persistence efforts continue to compound, the underlying earnings power of the platform is strengthening in really exciting ways. With respect to Chamberlain, last fall, we were direct with you. The market opportunity was solid, but our execution was not. We called out two issues, marketing effectiveness and funnel conversion. In response, we localized our marketing in key metropolitan areas, simplified the application experience, rebuilt the scholarship process, and upgraded talent in the critical roles across this activity set. We said we'd do these things, and we did. The operating signals are now telling the story. Application volumes have improved sharply. Funnel conversion is up. Total enrollment turned positive ahead of plan. We expect Q4 to look like Q3 with momentum building into the fall enrollment cycle.

We're not declaring victory on a single quarter of 0.5% enrollment growth, but we are telling you that the operating model is working, and the trajectory ahead is stronger than the trailing numbers suggest. Looking forward, 4 things matter at Chamberlain. The first is the admission pathway expansion that we've embarked on, including fast-track options that give students more flexibility in how they earn their degree. Second is campus expansion. 6 new campuses are in active development. The first begins teaching in September, and 2 have received full regulatory approval since Investor Day. Third is a new brand campaign for Chamberlain, which I expect will compound through fiscal 2027, both in enrollment growth and in the brand equity for Chamberlain. Last but not least is the addition of a dynamically capable new leader for the university, who I'll speak to in a moment.

Chamberlain confers more nursing degrees than any other university in the country. That's no accident, and it's not easily replicated. At Walden, the story is one of sustained momentum on top of very strong comparables. Total enrollment grew 12.3% to over 54,000 students, a record for that institution. The work I'm proudest of is what Walden has done on student persistence. We started by focusing on first to second semester retention, and we've since pushed the same discipline deeper into the student experience. It shows up in the retention numbers, and it compounds quietly over time, which is exactly the kind of operating asset we want to build. We launched several programs heading into the 2026 academic year, including clinical psychology and behavioral analysis, and they've already enrolled over 1,400 students.

7 additional programs were approved, 3 of which are starting intake shortly in fields like palliative care and special education. The speed at which Walden brings new programs to market in high-demand fields is a competitive advantage we intend to build upon. Medical and veterinary continues its strong performance. The top line is healthy, and the operating discipline keeps converting enrollment growth into strong financial outcomes. 1 operational point worth flagging: we've cut application review time by weeks through process improvements and workflow automation. Faster decisions mean a better applicant experience and a higher probability that strong candidates choose us. Our academic outcomes remain exceptional. We're tracking at a 97% first-time residency attainment rate, with AUC at over 98% in the most recent cycle.

On the veterinary side, our graduates continue to earn spots in the most competitive internships and residencies in the country, and we remain among the top universities in total veterinary placement. On our enterprise investments, our work with Google Cloud is moving forward on 2 fronts. First, we're co-developing the AI-powered classroom of the future, built natively inside the platform our students already use. The goal is a personalized learning companion that supports each student from first course to graduation. Initial pilots launch later this year. Second, more than 4,000 learners have already enrolled in our newly launched AI credentials across nursing, medicine, and foundational AI. Additional certificates in veterinary medicine, mental health, and other disciplines launch later this year. The demand validates how urgently the healthcare workforce wants AI fluency.

To keep this work grounded in clinical reality, we established the Covista Healthcare Readiness AI Council, with leaders including Dr. Toby Cosgrove, former CEO of Cleveland Clinic, Dr. Selwyn Rogers of University of Chicago Medicine, and Dr. Betty Jo Rocchio, Chief Nurse Executive at Advocate Health. Building the most clinically grounded AI curriculum in healthcare education is our objective, and it's increasingly a differentiator that's resonating with health systems. Before I hand off to Bob, I do want to spend a moment on capital because how we allocate it is central to how we create value for you. Trailing 12-month free cash flow grew 17% to $336 million. We refinanced our long-term debt during the quarter, cutting 50 basis points off our rate and extending maturity to 2033.

We repurchased $66 million of our stock in the quarter at prices we believe materially understate the long-term earnings power of this platform and are accretive to our intrinsic value. We ended the quarter at 0.7 times net leverage. That balance sheet, combined with the cash this business generates, gives us multiple paths to create value at the same time: investment in campus expansion, employer partnerships, and the AI platform, opportunistic return of capital to shareholders, and the optionality to act decisively if the right strategic opportunity presents itself. We'll be disciplined about which dollar goes where, and we'll be transparent about the choices we make. On leadership, two important notes. Amelia Manning will join Chamberlain as its next president, bringing the student success operating discipline she developed as COO of Southern New Hampshire University.

Michael Betz will take on an expanded role as Chief Growth and Innovation Officer, adding marketing oversight to his leadership of Walden and our digital work. Both moves strengthen our ability to execute, and I have high conviction in both leaders. To summarize, we delivered strong performance across every segment. Chamberlain has turned. Walden continues to compound. MedVet is converting growth to financial outcomes. The capital structure is in great shape. The cash generation supports the investments we're making, and structural demand for what we produce is durable and deepening. As we close the fiscal year, we will complete our three-year Growth with Purpose strategy in a position of strength and move into Purpose at Scale. That next chapter is built on four pillars: operational excellence, platform extension, employer integration, and technology focus.

You heard the framework at Investor Day, the point I want to leave you with today is a bit simpler. Purpose at Scale is not a plan we're about to roll out for the first time. It's an extension of the operating model that's already producing this quarter's results, you'll see that same discipline at a larger scale over the coming quarters. As always, thank you for your continued support, now I'll turn the call over to Bob.

Thank you, Steve. Our third quarter results reflect continued execution against our Growth with Purpose strategy and set the stage for our next chapter. We delivered strong financial performance, raised our revenue outlook, for the second straight quarter, raised our adjusted earnings per share guidance. We continue to benefit from a robust financial foundation while increasing our level of profitability through scale and operational excellence, all while deploying capital in a balanced and disciplined fashion. I'll now review our financial results and key drivers for the third quarter. Later in my remarks, I'll discuss the updated expectations and assumptions for the remainder of fiscal year 2026. Starting with the top line, revenue in the third quarter increased 4.5% to $487 million, driven by enrollment growth across all three segments.

As we flagged last quarter, Walden's results were impacted by the shift of 1 academic week from the third quarter into the second quarter this fiscal year. This resulted in $18 million of revenue being recognized in Q2 rather than Q3. Excluding this 1-week timing impact, consolidated revenue would have increased 8.4% year-over-year. On a comp basis, the organic trajectory of the business is tracking extraordinarily well. Consolidated adjusted EBITDA came in at $127.9 million. As with revenue, the 1-week Walden calendar shift had a meaningful impact on our third quarter margin profile as well. Excluding the timing impact, consolidated adjusted EBITDA would have increased 14.2% to $145.9 million, and consolidated adjusted EBITDA margin would have been 28.9%, up 150 basis points from the prior year. Adjusted EBITDA growth was led by Walden, adjusting for the 1-week shift with both Chamberlain and MedVet contributing as well.

Adjusted operating income was $102.2 million. Excluding the one-week Walden revenue shift, adjusted operating income would have increased 14.1% compared to the prior year to $120.3 million as revenue growth and efficiencies generated operational leverage, which is partially offset by investments in our strategic growth initiatives. Adjusted net income for the quarter was $69 million. Adjusted earnings per share was $1.98 and was also impacted by the Walden calendar shift. Let me turn to our third quarter financial highlights by segment. Chamberlain reported third quarter revenue of $197 million, an increase of 2.3% compared with the prior year. Total student enrollment grew 0.5% to 40,767 students, reflecting Chamberlain's return to positive total enrollment growth, an important milestone as operational improvements we put in place earlier this fiscal year continue to gain traction.

Chamberlain's return to positive total enrollment growth also coincides with the highest enrollment in university history. This was driven largely by pre-licensure, where we achieved our 15th straight quarter of total enrollment growth, reinforcing the durability of Chamberlain's positioning in that market. While post-licensure was lower, we experienced sequential improvement in RN to BSN and continued growth in the master's program. Adjusted EBITDA for Chamberlain increased 2.9% to $58.5 million. Adjusted EBITDA margin of 29.7% expanded 20 basis points versus the prior year. We will continue to invest in Chamberlain's marketing and enrollment operations as well as into our new campus development, as discussed at Investor Day. Turning to Walden, as we noted last quarter, second quarter results had benefited from the one-week academic calendar shift, and this third quarter reflects the opposite impact. Third quarter revenue was $186.6 million, an increase of 4.6% versus the prior year.

Excluding the $18 million revenue timing impact, Walden revenue would have increased 14.7% year-over-year to $204.6 million, reflecting the strong underlying enrollment growth. Total student enrollment grew 12.3% to 54,474 students, joining Chamberlain in also setting a record this quarter and marking Walden's 11th consecutive quarter of total enrollment growth. This was attributable to broad-based gains across healthcare and non-healthcare programs and continued strong persistence rates. Adjusted EBITDA was $49.7 million. Excluding the one-week revenue shift, Walden adjusted EBITDA would have increased 25.5% to $67.8 million, and adjusted EBITDA margin would have been 33.1%, up 280 basis points, reflecting the powerful operational leverage inherent in Walden's model. For the medical and veterinary segment, third quarter revenue was $103.5 million, an increase of 8.9% versus the prior year. Total student enrollment increased 4.1% to 5,344 students, with growth in both our medical and veterinary programs.

Adjusted EBITDA increased 20.1% versus the prior year to $27.5 million. Adjusted EBITDA margin of 26.5% expanded 250 basis points versus the prior year, as we remain focused on operating our institutions efficiently while making long-term growth investments and delivering strong academic outcomes. Shifting to cash flow and balance sheet, our trailing 12-month free cash flow was $336 million, up 17% from the comparable year-over-year 12-month period, reflecting the strength of our operating model and high cash conversion. net leverage declined to 0.7 times as of March 31, 2026, with cash and equivalents of $147 million.

During the quarter, we refinanced our long-term debt, consolidating into a $510 million Term Loan B with a 50 basis point improvement in rates while also extending the maturity to 2033. Our strong cash generation and healthy balance sheet continue to give us the flexibility to deploy capital toward high return growth opportunities while returning excess cash to shareholders, including share repurchases of $66 million during the quarter. Based on our year-to-date performance and our expectations for the fourth quarter, we are raising both revenue and adjusted EPS guidance for the full year. Revenue is now expected in the range of $1.93 billion-$1.945 billion, up from our prior range of $1.9 billion-$1.94 billion. This reflects revenue growth of 8%-9% for the full year.

Adjusted earnings per share guidance is being raised to a range of $7.95-$8.15, up from the prior range of The raised guidance reflects strong momentum across each of our segments, including our expectation for positive fourth quarter enrollment growth at Chamberlain, which we expect to look like our third quarter enrollment performance. Our guidance also reflects an elevated level of targeted strategic growth investments in the fourth quarter across our institutions that we believe positions us well heading into fiscal year 2027. The increase in adjusted earnings per share guidance also contemplates our continued commitment to expanding our fiscal year 2026 adjusted EBITDA margin by 100 basis points. We continue to anticipate an effective tax rate higher than fiscal year 2025.

We remain focused on executing against our strategic and financial goals, expanding access, delivering positive student outcomes, deploying capital to meet the growing demand in healthcare education, and generating strong long-term returns for all stakeholders. With that, I'll now turn the call over to the operator for Q&A.

Thank you. With that, we will now be conducting a question-and-answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate that your line is in the question queue. You may press star two if you wish to remove yourself from the queue. For any participants using speaker equipment, it may be necessary to pick up the handset before pressing the star keys. One moment while we poll for questions. Our first question comes from the line of Jeff Silber from BMO Capital Markets. Please proceed with your question.

Hey, thank you so much. This is Ryan on for Jeff Silber. You'd spoken about the strength of the SSM partnership at the recent Investor Day. I was just wondering if you have an update on that or any of the other employer partnerships, and then how the conversations with the care providers have been going since we last spoke.

What I can say about SSM is that the relationship continues to thrive. The sort of interest, the increase in applications and inquiries around the St. Louis campus have been really encouraging. No specifics to share at this point, but it continues to be a great proof point of a new and differentiated way of thinking about talent acquisition for healthcare providers. Beyond SSM, we've got several conversations active around the country, and we hope to be able to announce new partnerships in the near term. We're very encouraged by the outcomes that we're seeing in the early days at SSM and the interest that we're receiving from other providers.

Thank you. just looking at the magnitude of the quarterly beat, and then with your comments on the targeted investment in 4Q, was wondering if there was any timing of expenses that you pushed out into 4Q from 3Q.

No, the way I would characterize it is, we do have a dynamic resource allocation model. We look at investments on a regular basis, and we're just making incremental investments in the fourth quarter, is really the way to look at it, as opposed to just shifting things from the third to the fourth.

Thank you. Our next question comes from the line of Jasper Bibb from Truist Securities. Please proceed with your question.

Hey, good afternoon, guys. you know, really nice to see Chamberlain returning to growth here. Can you just talk about, you know, the drivers of that and then the RN to BSN piece, what you're seeing for demand in that segment as well as your own performance in the quarter?

Again, two quarters ago, you know, we let you know that we had what we thought was an underperforming enrollment cycle in Chamberlain. We thought we had identified the root causes of that, all of which that we determined were in our own control. A quarter later, we gave you a sense of how that remediation was working, talking you through some of the leading indicators of enrollment there. We let you know that we thought you'd see that in the results of operations as we began to exit the fiscal year. We're really pleased that that remediation work has taken root in a way that allows us to go total enrollment positive a quarter sooner than we thought. We're really pleased about what that means for the go-forward momentum for Chamberlain.

You know, all year, pre-licensure nursing at Chamberlain University had been a bright spot for us. We had plenty of strength there. What we were really focused on was the trends in post-licensure nursing, the largest piece of which, as you know, is our RN to BSN program, as well as our other postgraduate programs. I'm really pleased to say that we've got great momentum in both of those categories. RN to BSN is not the growth category that it may have been 7 or 8 years ago, we are the leader in that space. As I indicated in prior calls, we have every intention of defending our leading position in that category.

Pleased to see the early momentum show up in our reported results, and look forward to seeing that momentum continue into Q4 and into the all-important fall enrollment cycle.

I know those applications were up double digits again at Chamberlain. That seems like a nice signal, you know, ahead of the fall enrollment cycle. Have you seen the conversion from those applications normalize back toward, I guess, historical levels, or is it maybe too early to say that?

The short answer is yes. As you'll recall, you know, we identified 2 categories of challenges. One was at the top of the funnel related to the marketing campaign that we launched a couple of quarters ago that underperformed. As you also know, I mentioned at the time that we had record low conversion, all of which, in our view, is an execution failure. We have fixed that. The fact of the matter is, we are seeing conversion rates that are much more consistent with historical conversion rates. That's really a reflection of what we've done on a personnel training and process basis at the bottom of the funnel. Just to clarify 1 point I made earlier about post-licensure nursing in response to an earlier question.

Just to be clear, our MSN programs in post-licensure are actually larger than RN-BSN, but RN-BSN is a really, really important category for us, and we will defend our position there.

Got it. Last one for me. I think you said Chamberlain's fiscal fourth quarter should look like the third quarter from an enrollment perspective. Just to clarify, was that saying the absolute enrollment number in the fourth quarter should be similar to the third quarter or the year-over-year growth rate in enrollment should be similar to the third quarter? Thank you.

We expect the rate of growth to be directionally similar.

Okay. Got it. Thank you.

Thank you. Our next question comes from the line of Jack Slevin with Jefferies. Please proceed with your question.

Hey, good afternoon, guys. Congrats on the strong quarter.

Thank you.

Maybe just to drop in on Chamberlain again, but ask it slightly differently. Obviously, performance a little better than we have expected. Leading KPIs seem to be positive. Now, the incremental commentary there, Steve, on the conversion side. I guess, as you look at the next, you know, call it four months here, as you roll into the September enrollment cycle, for 2026, like, what are the key focus points that you need to sort of, you know, stay present on in order to drive that inflection that you've been talking about and sort of have a better year than you did last year?

I think it really comes down to execution. Chamberlain occupies an enviable position in nursing education. It's got incredible brand equity that resonates with both students and employers alike. It's got a fantastic mix of programs across pre-licensure and post-licensure nursing. It's a fantastic brand and a fantastic product to take to market. It's really about executing in the way that we've historically been accustomed to. The fall enrollment cycle 2 quarters ago was an anomaly for Chamberlain. Chamberlain's a high-performing organization, and we feel that from a personnel and a process perspective, we are exactly where we should be. We're also welcoming a new president to Chamberlain, who will start work in earnest next week. We're really excited about what she will bring to the momentum at Chamberlain.

As I said back at Investor Day, Chamberlain's best days are ahead of it, and we look forward to proving that out quarter in and quarter out.

Awesome. Very, very helpful. Then it-- this might be a little early, then if anything goes, you know, the way that it did after their last Investor Day, then this question might come up fairly frequently. You know, upside in the quarter, you put out targets that are year-over-year that sort of stack on top of each other. You know, is it fair to say, as we look towards the 27 numbers, that you still feel good about what you put out at Investor Day, even with the higher base coming through now on the raised guidance?

Yeah, I mean, philosophically, you know, our view is that we want to put out targets that represent aggressive stretch goals for the organization, that represent the art of the possible for our assets and for our people. We feel good about the three-year targets we put out directionally at Investor Day. Obviously, as we get to fiscal 2027, we'll have a full year guide for that year, as we open the year, and that will reflect our best estimate of both the momentum in the business and the market opportunity in front of us. We'll be able to provide a bit more precision on fiscal 2027 at that time.

Okay, got it. Last one. Steve, really helpful color on sort of where things sit in the pipeline of all the campus expansion you've talked about. Is there any way to think about, notice the step-up in CapEx in the quarter. Is there any way to think about, as you start to roll out those 10-15 eventual campuses in the plan, you know, multi-year plan, where CapEx levels, you know, roughly should be shaking out on a run rate basis? Any way to think about maybe just the next, you know, call it 2-4 quarters as we model things out? Thank you.

Sure. I'll take that one. What I would tell you is if you look at by quarter the CapEx spend this year, you see the ramp up. I mean, we spent $31 million in the first half of the year. We spent $20 million in the third quarter. What I would tell you is that I would expect the fourth quarter to ramp up further from where we were in the third quarter. Then if you take that into next year, that would be, you know, a good proxy for what to expect going forward.

Got it. Helpful color. Congrats again on the quarter.

Thank you.

Thank you. With that, this does now conclude our question and answer session. I would like to turn the floor back to Steve Beard for any closing remarks.

Thank you. We have the good fortune of coming out with earnings today in the middle of National Nurses Week. As the largest nursing educator in the U.S., we just want to take a moment to salute nurses everywhere. They are a critical component of care delivery in the U.S. It's a calling and a profession that we all rely upon. So, a sheer thanks to all of the nurses and also a shout-out to all of the aspiring nurses at Chamberlain and Walden across the country. Thank you so much.

Thank you. With that, ladies and gentlemen, this does conclude today's teleconference. We thank you for your participation. You may disconnect your lines at this time, and have a wonderful rest of your day.

Greetings and welcome to the Adtalem Global Education Inc. Second Quarter 2026 Earnings. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jay Spitzer, VP of IR. Thank you, Jay. You may begin.

Good afternoon, and welcome to our earnings call for the second quarter fiscal year 2026 results. On the call with me today are Stephen W. Beard, Chairman and Chief Executive Officer of Adtalem Global Education Inc., and Robert J. Phelan, Chief Financial Officer. Before I hand you over to Stephen, I will, as usual, take you through legal safe harbor and cautionary declarations. Certain statements and projections of future results made in this presentation constitute forward-looking statements that are based on current market, competitive, and regulatory expectations and are subject to risks and uncertainties that could cause actual results to vary materially. We undertake no obligation to update publicly any forward-looking statement after this presentation, whether as a result of new information, future events, changing assumptions, or otherwise. Please see our latest Form 10-K and Form 10-Q for discussions of risk factors as it relates to forward-looking statements. In today's presentation, we use certain non-GAAP financial measures, and we refer you to the appendix of the presentation materials available on our Investor Relations website for reconciliations to the most directly comparable GAAP financial measures and related information. You will find a link to the webcast on our Investor Relations website at investors.adtalem.com. After this call, the presentation webcast will be archived on the website for thirty days. I will now hand you over to Stephen. Thanks, Jay. Good afternoon, everyone, and thank you for joining us.

This quarter marks our tenth consecutive quarter of enrollment growth. We remain on track to achieve our full-year revenue guidance of 6% to 8.5% growth, and we are raising our adjusted earnings per share guidance to 17% to 20% growth. As we enter 2026, we continue to execute against our strategic roadmap. Our strong second-quarter results reflect that execution. The momentum we have built over the last several years is proving sustainable, demonstrating the power of our differentiated business model. Our consistent performance, strong balance sheet, and robust cash generation power a value-creating capital allocation philosophy. This quarter, we deployed $165 million to share repurchases, and we have approximately $728 million remaining on our current authorization. We will continue to take a disciplined, returns-focused approach to capital allocation. Our focus on students and investments in modern innovative learning continue to yield strong academic, operational, and financial outcomes. Walden has achieved record total enrollment. More than 52,000 students now generate industry-leading scale and operating leverage. Chamberlain expanded its reach as the national leader in nursing, growing enrollment by 6,000 students in just three years to reach a record of 40,000 students. Ross Vet continues to graduate more veterinarians than any other school, and AUC and Ross Vet together graduate twice as many physicians as any MD-granting school in the United States. Simply put, we have established the quality and scale to be a trusted leader in healthcare talent development and an essential component in tackling America's healthcare workforce shortage. Now let me zoom out. We all read the headlines. The healthcare workforce crisis is not easing. It is intensifying. America's healthcare system begins 2026 substantially understaffed, with workforce gaps expected to deepen. The challenge exists everywhere but is particularly acute in rural communities and underserved urban areas where continuity of care and access are already fragile. The stakes for the entire healthcare system could not be higher. Tackling a crisis of this magnitude requires workforce infrastructure that operates at a different scale than traditional academic institutions. And that is precisely where our opportunity lies. At our Investor Day on February 24, we will lay out our multiyear growth framework, including capacity expansion plans and new revenue streams, that position us to meet these societal needs while delivering sustainable earnings growth. Now let me walk through our second-quarter performance. Total enrollment grew over 6% to 97,000 students. Revenue grew 12% to $503 million. We delivered further efficiencies as adjusted EBITDA grew to $155 million. Our solid profitability, together with disciplined capital allocation, has yielded adjusted earnings per share of $2.43, an increase of 34% versus last year. Growth with purpose remains our durable operational framework yielding clear academic, operational, and financial returns. Our strategy to optimize existing capacity has yielded record or near-record enrollments at Walden and Chamberlain and has positioned the MedVet segment for sustainable growth. More importantly, we believe the success of Growth With Purpose has earned us the permission to expand our leading position and invest in solutions that address US healthcare workforce shortages while sustainably growing earnings for years to come. With that context, let me turn to our segment results. At Chamberlain, we are confident in our trajectory. Q3 total enrollment will remain soft, and recent improvements work their way through the student journey, but the real proof point is the fall enrollment cycle. Let me explain why we like what we are seeing. Chamberlain's fundamentals remain exceptionally strong. Over the past two years, Chamberlain added 5,600 new students and grew revenue by $155 million, a 27% increase. We hit record enrollment nine months ago. This quarter's negative 1% total enrollment and the relatively flat growth we expect over the balance of the year represents a temporary pause in that trajectory, not a reversal of it. Over the last three years, we successfully launched new campuses in Atlanta and Kansas City, relocated our Phoenix campus, and built our national online BSN program to more than 4,200 students across 38 states in just four years. Together, these moves have maintained or grown our market-leading positions. We are number one in BSN, number three in RN to BSN, number one in masters, number one in the doctoral category. This is a testament to the performance and scale foundation that sets Chamberlain apart. Last quarter, I identified two execution gaps: marketing effectiveness and enrollment funnel conversion. We moved swiftly to address both, and early indications are encouraging. Application volumes for both prelicensure and postlicensure nursing programs are up double digits during the second quarter, running ahead of where we were at this point last year. On marketing, we optimized spend, improved our website, and streamlined scholarship offerings so students can research programs with a clearer picture of net cost of attendance. And our focus on a more seamless prospective student experience has increased funnel conversion. We are moving forward with precision and operational accountability. But here is what matters. We expect this application momentum will translate into new enrollment growth and position us well heading into the critical fall cycle. At Walden, we delivered our tenth consecutive quarter of enrollment growth, up 13% in the second quarter. As a result, we achieved record total enrollments of 52,400 students. Similar to prior quarters, Walden's digital learning platform and flexible offerings continue to demonstrate strength as we innovate and deliver an increasingly seamless experience for working adults. Building on this momentum, we launched several new programs heading into this academic year. Programs such as the master in applied behavioral analysis and the master's degree in clinical psychology are attracting working professionals who want to make meaningful societal contributions. Overall, our new programs have already enrolled more than 1,002 students in less than one year, with additional programs in the development pipeline that we expect to roll out soon. Last quarter, I highlighted that we streamlined our professional doctoral programs, creating a more seamless student experience with a simplified tuition structure. Building on that, we recently launched the Walden University PhD completion program, designed for doctoral students who left their original program before finishing their dissertation. We are now providing a channel for them to reach the finish line and earn their degree with us. These enhancements showcase our commitment to drive meaningful impact for thousands of students. Turning to our medical and veterinary segment. The second quarter is an enrollment period, but we are seeing momentum in leading enrollment indicators. At our medical schools, we are executing on two fronts: creating innovative pathways that expand access and remove barriers to the MD program, and driving operational excellence in our enrollment funnel. This sets us on a sustainable trajectory of enrollment growth. Leveraging technology and artificial intelligence in our basic sciences curriculum enables a higher precision learning environment. Combined with our capstone program, this has yielded enhanced student outcomes through increases to our USMLE step one pass rates. Ross Vet continues to operate at near capacity, maintaining its position as a leader in veterinary education, with a one-of-a-kind experiential learning model. And Ross Vet has also increased its NAVLE pass rate. In closing, let me come back to where I began. As America's largest healthcare educator, we are uniquely well-positioned to address substantial and growing healthcare workforce shortages at scale. Our combination of program breadth, geographic reach, and proven outcomes is unparalleled. Finally, I want to acknowledge the unwavering commitment of our 10,000 colleagues, 97,000 students, and 385,000 alumni. They make all of this possible. And with that, I'll turn the call over to Robert J. Phelan, our CFO.

Thank you, Stephen, and hello, everyone. Halfway through fiscal year 2026, we are executing against our growth with purpose strategy, putting us on track to meet our full-year financial goals. Importantly, we continue to enhance our financial foundation and increase our level of profitability by generating efficiencies through scale and operational excellence. This, in turn, is delivering significant cash flow and a more flexible balance sheet. Our robust financial performance is also allowing us to deploy capital in a balanced fashion, whether through share repurchases, debt repayment, or through investments in high ROI additional growth opportunities, including bringing new capacity to market and providing innovative student-facing technology. Taken together, we continue to build strategic momentum that supports long-term value creation. I'll now review the financial results and key drivers for our second quarter. Later in my remarks, I'll discuss our expectations and assumptions for the remainder of fiscal year 2026. Starting with the top line, revenue in the second quarter increased by 12.4% to $503.4 million, driven by all three segments. Walden continues to be a source of strength and, in particular, was aided by a one-week academic calendar shift from the third quarter into the second quarter this fiscal year, resulting in an incremental $18 million in revenue recognized in Q2 rather than in Q3. Excluding the one-week shift, revenue was up 8.4% versus last year for Adtalem. Consolidated adjusted EBITDA came in at $154.9 million, up 23.9% compared to the prior year. This growth was led by Walden, which again includes the incremental week, with MedVet contributing partially offset by Chamberlain. Adjusted EBITDA margin of 30.8% expanded 290 basis points from last year. Excluding the incremental one-week consolidated adjusted EBITDA margin was up 30 basis points year over year. Adjusted operating income was $126.1 million, up 24.3% compared to the prior year, as revenue growth and efficiencies generated operational leverage, which was partially offset by investments in our strategic growth initiatives. We continue to balance our strategic growth investments with a more efficient, integrated, and scaled operational foundation. Adjusted net income for the quarter was $87.9 million, up 26.7% compared to last year, attributed to adjusted operating income growth, lower interest expense resulting from our actions to reduce outstanding debt and our borrowing costs, and partially offset by a higher provision for income taxes. Adjusted earnings per share was $2.43, or a 34.3% increase compared with the prior year. We repurchased 1.7 million shares of our common stock at an average price of $95 within the quarter, resulting in an average diluted shares outstanding of 36.2 million, or approximately 2.2 million lower than last year. This completed our prior $150 million authorization, and we subsequently announced a new $750 million board authorization through December 2028, which has $728 million available as of December 31. Our strong operational and financial discipline, coupled with our high cash conversion rate, resulted in a trailing twelve months operating cash flow generation of $428 million, up $146 million from the comparable year-over-year last twelve-month period. Our strong cash flow and healthy balance sheet is affording us the ability to deploy capital, to invest in the long-term profitable growth of our business, as well as return capital back to our owners. We believe these actions have and will continue to increase long-term intrinsic value for the benefit of our shareholders. Next, I'll discuss the second-quarter financial highlights by segment. Chamberlain reported second-quarter revenue of $183.8 million, an increase of 1.6% compared with the prior year, driven by pricing optimization. Total student enrollment during the quarter declined by 1% as growth in pre-licensure programs was offset by declines in post-licensure programs. Our pre-licensure BSN programs have grown for fourteen consecutive quarters as investments to grow our BSN online offering are yielding promising returns. Post-licensure nursing was lower from declines in the RN to BSN program, partially offset by growth in our master's programs. As Stephen noted, Chamberlain applications during the quarter improved significantly, an encouraging trend that we expect to position us well for future enrollment. Adjusted EBITDA for Chamberlain decreased by 14% to $45.2 million for the quarter, adjusted EBITDA margin of 24.6% was lower compared to the prior year as we make investments focusing on bringing new capacity to market and continue to invest in our students to support enrollment growth and academic outcomes. Turning to Walden, second-quarter revenue of $217.6 million, an increase of 27% versus the prior year, was driven primarily by strong growth in enrollments aided by the aforementioned one additional week of revenue during the second quarter. Excluding the additional $18 million from the one-week shift, Walden revenue was up 16.5% versus last year. Total student enrollment was up 13% compared to the prior year, the tenth consecutive quarter of growth. This was driven by robust enrollment growth across all degree levels, particularly in master's and undergraduate, and continued high persistence rates. Growth in our healthcare programs was led by both social and behavioral health and nursing. Our non-healthcare programs also grew in the quarter. Adjusted EBITDA increased by 66.5% to $86.7 million. Adjusted EBITDA margin expanded by 940 basis points versus the prior year, to 39.8%. Excluding the one-week revenue shift, Walden's adjusted EBITDA margin expanded approximately 400 basis points as our operational excellence generated efficiencies and leverage that outpaced increased brand and student-facing digital investments, and additional student support commensurate with the high level of new enrollment. For the medical and veterinary segment, second-quarter revenue was $102 million, an increase of 6.9% versus the prior year. As Stephen mentioned, there is no change in the student enrollment for the second quarter compared with the first quarter given term starts. Adjusted EBITDA increased by 17.6% versus the prior year to $31.4 million. Adjusted EBITDA margin increased 280 basis points versus the prior year to 30.8% as we remain focused on operating our institutions efficiently while making long-term growth investments that leverage our existing capacity, creating new enrollment pathways, and delivering academic outcomes. Based on the year-to-date performance and our expectations for the balance of the year, we are maintaining our annual revenue guidance as we continue to grow our business on top of strong enrollment levels. Revenue is expected in the range of $1.9 to $1.94 billion, or approximately 6% to 8.5% growth year over year. As I mentioned earlier in my remarks, we had a one-week shift in the academic calendar resulting in Walden recording one additional week of revenue in the second quarter and one less week in the third quarter. The $18 million shift between the quarters benefited the second quarter while it will reduce the third quarter but overall, has no net impact on our annual performance. In addition, the revenue guidance also continues to reflect our prior comments related to enrollment and revenue growth being higher in the first half of the year as we lap double-digit comps from last year, particularly the strong comps from last third quarter. Our reiterated revenue guidance contemplates Chamberlain's top-line impact, and while operational improvements are resulting in application volumes growing year over year in the second quarter at Chamberlain, the financial impact is not immediate. But we do expect application growth to translate to future quarters' new enrollment growth. And finally, strength in Walden's top line is anticipated to continue to deliver robust growth. We are raising our adjusted EPS guidance from the previous range of $7.60 to $7.90 or growth of 14% to 18.5% to a range of $7.80 to $8.00 or growth of 17% to 20%. At the midpoint, our adjusted EPS range is increasing by $0.15. The increase in adjusted EPS guidance contemplates our continued commitment to expanding our fiscal year 2026 adjusted EBITDA margin by approximately 100 basis points. We expect quarter-to-quarter margins will fluctuate with a higher level of targeted investments being made in the third quarter and less investment in the fourth quarter. Further, the one-week Walden revenue shift into the second quarter will have a pronounced impact on our third-quarter margin profile. The raised adjusted EPS guidance also incorporates our capital allocation actions and continued strong cash flow generation. And we continue to anticipate an effective tax rate to be higher than fiscal year 2025. Overall, we will continue to execute on expanding access, delivering positive student outcomes, deploying capital to meet the healthcare education market's growing demand, maximizing long-term value, and ultimately generating high returns for all stakeholders. As Stephen noted, I look forward to discussing our longer-term targets at our upcoming Investor Day. And with that, I'll now turn the call over to the operator for Q&A.

Thank you. We will now be conducting a question and answer session. Thank you. Our first question comes from the line of Jeffrey Marc Silber with BMO Capital Markets. Please proceed.

Thank you so much. I'm actually going to start with Walden. I'll let some other folks focus on Chamberlain. Even excluding the calendar shift, the Walden numbers continue to impress. Can we just double-click on that? What exactly is going on? Where are you seeing the growth? Do you think you're taking share from other schools in this market?

Yes. So, the Walden growth is consistent across the board, but we see it most pronounced in the areas that we've consistently been most excited about. That's in the behavioral sciences programs and also in the nursing program and the MSN credential. To a lesser extent, you know, we're seeing great returns on our investments in the education programs at Walden. As we increasingly look to expand that institute, undergraduate enrollments, we're having great traction there as well. So really pleased with the balanced growth across the program mix at Walden.

Okay. And then maybe shifting to one of the regulatory issues. We're expecting some changes in the loan caps this July. I know you had announced an earlier partnership with Sallie Mae. Can we get an update in terms of what's going on there?

Yeah. We're working with Sallie Mae on definitive documentation for that partnership. Sallie Mae has also been working to pull together the syndicate of capital sources that will actually provide the loan dollars. But we continue to be excited about that partnership and what it means for the entire portfolio, including the medical and veterinary segment. We're obviously expecting to have to utilize supplemental lending sources the most. So more to come on that, but we continue to move at pace with them, and we'll be excited to announce definitive documentation once it's complete.

Okay. Great. I'll jump back in the queue. Thanks.

Thank you. Our next question comes from the line of Jack Garner Slevin with Jefferies. Please proceed.

Hey, guys. Congrats on the quarter and thanks for taking the question. I am going to decide to dig in on Chamberlain a little bit. So if we just look, you know, really encouraging sign on the double-digit growth. I guess the immediate question becomes sort of if you could remind us of what that typical lead time is, and I'm hearing the emphasis in the fall cycle, but maybe just walking a little more detail on sort of, you know, what exactly is going right as you're, you know, you've enacted some of those changes you called out last quarter and then whether or not that sort of, you know, lags through the second half and then see the rebound or, you know, sort of an inflection around the fall cycle tracks to what you typically would expect? Thanks.

Happy to speak to it. As we said before, we identified a couple of gaps: marketing effectiveness and enrollment funnel conversion. We took a number of steps to address processes on both dimensions. And as you'll note, we also took a number of steps to make changes in personnel across the Chamberlain organization. We feel really good about the implications of those moves. As I said in the prepared remarks, some of the leading indicators of enrollment have been really positive. Application volumes up for both pre-licensure and post-licensure nursing programs. You have to remember that fall cycle is the biggest cycle of the Chamberlain fiscal year. And it creates a big hole to dig out of. But we are confident in the trajectory of the recovery. So while we expect the total enrollment story on a quarter-over-quarter basis to be flat over the balance of the fiscal year, we do expect as we approach that fall enrollment cycle to be in a position to go back to a positive total enrollment year over year and get back to a total enrollment trajectory consistent with what we've enjoyed in the last few cycles. So we think we have the situation well in hand. We feel good about the early signals we're seeing, and we're confident that we exit the fiscal year moving towards a positive total enrollment growth in Chamberlain, with the benefit of a robust trajectory in pre-licensure and a return to form in post-licensure nursing.

Got it. Okay. Really helpful, Stephen. One more for me here. You know, I guess, running some quick numbers. The last few years, you've seen roughly $60 million of improvement in revenues second half versus first half. Obviously, you have the Walden callout, right, on the timing of that one-week impact. But even adjusting for that, it looks like the high end of the guide at about $45 million. Guess I'd just be curious to sort of describe what the scenario would play out that would see you sort of meet or exceed the high end of that guide? Is it simply Chamberlain coming in a little ahead or really, you know, where you could envision that upside potentially coming from if it were to materialize? Thanks.

Yeah. I think it would come from a quicker than anticipated return to form at Chamberlain and potentially some additional acceleration in the trajectory at the MedVet segment. We think we're moving at sort of an optimal clip at Walden, so it would come from the other two segments.

Okay. Got it. Super helpful. Congrats again on the quarter and looking forward to seeing you at Investor Day. Thank you. I appreciate it.

Thank you. There are no further questions at this time. I'd like to pass the call back over to Stephen for any closing remarks.

Yes, I want to do two things. First, thank all of our colleagues across the Adtalem Global Education Inc. portfolio for all of their incredible work over the course of the last quarter. We've come back from the break in the calendar year to hit the ground running aggressively. I also just want to put out a plug for our upcoming Investor Day on February 24. We've got a lot of news that we're prepared to share. We're really excited about it. We look forward to having you all participate virtually or in person. Thank you so much.

Thank you. This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation.